Table 1.
Association between clinicopathological features and S-1 administration duration
| (%) | S-1 administration duration | P | |
|---|---|---|---|
| 4 courses | >4 courses | ||
| Total | 99 (60.7) | 64 (39.3) | |
| Sex | 0.473 | ||
| Male | 50 (50.5) | 36 (56.3) | |
| Female | 49 (49.5) | 28 (43.8) | |
| Age (years) | 0.692 | ||
| ≤ 65 | 51 (51.5) | 35 (54.7) | |
| > 65 | 48 (48.5) | 29 (45.3) | |
| CA19.9(IU/mL) | 0.252 | ||
| < 37 | 28 (28.3) | 13 (20.3) | |
| ≥ 37 | 71 (71.7) | 51 (79.7) | |
| Tumor location | 0.295 | ||
| Head/neck/uncinate | 65 (65.7) | 47 (73.4) | |
| Body/tail | 34 (34.3) | 17 (26.6) | |
| Grade | 0.865 | ||
| 1/2 | 86 (86.9) | 55 (85.9) | |
| 3 | 13 (13.1) | 9 (14.1) | |
| Lymphovascular invasion | 0.772 | ||
| Without | 77 (77.8) | 51 (79.7) | |
| With | 22 (22.2) | 13 (20.3) | |
| Perineural invasion | 0.865 | ||
| Without | 13 (13.1) | 9 (14.1) | |
| With | 86 (86.9) | 55 (85.9) | |
| T stage | 0.814 | ||
| 1 | 18 (18.2) | 12 (18.8) | |
| 2 | 55 (55.6) | 38 (59.4) | |
| 3 | 26 (26.3) | 14 (21.9) | |
| N stage | 0.473 | ||
| 0 | 59 (59.6) | 32 (50.0) | |
| 1 | 33 (33.3) | 27 (42.2) | |
| 2 | 7 (7.1) | 5 (7.8) | |
| TNM stage | 0.794 | ||
| I | 44 (44.4) | 25 (39.1) | |
| II | 48 (48.5) | 34 (53.1) | |
| III | 7 (7.1) | 5 (7.8) | |
| R status | 0.072 | ||
| 0 | 90 (90.9) | 52 (81.3) | |
| 1 | 9 (9.1) | 12 (18.8) | |
| Chemotherapy regimens | 0.528 | ||
| S1 only | 87 (87.9) | 53 (82.8) | |
| S1 + gemcitabine | 6 (6.1) | 4 (6.3) | |
| S1 + other drugs | 6 (6.1) | 7 (10.9) | |
Abbreviation: TNM Tumor–node–metastasis